November 8, 2023

Afimmune to present at the American Society of Hematology (ASH) Annual Meeting after initiating recruitment in Sickle Cell Disease trial

Dublin, Ireland, 8 November 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that recruitment has commenced in the first clinical […]
September 18, 2023

Afimmune’s Epeleuton is granted both FDA Rare Pediatric Disease and Fast Track Designations for the treatment of Sickle Cell Disease

Dublin, Ireland, 18 September 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted […]
June 19, 2023

Afimmune joins the Sickle Cell Disease Association of America’s Collaboration of Advocates for Research, Education and Science (C.A.R.E.S.) Consortium

Dublin, Ireland, 19 June 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced it has been invited to join the Sickle Cell Disease […]
June 5, 2023

Data Showing Epeleuton Reduces Endothelial Adhesion Of Red Blood Cells From Sickle Cell Disease Patients Will Be Presented At The EHA 2023 Congress

Dublin, Ireland, 5 June 2023: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at the European Hematology […]
March 29, 2023

Afimmune to Host KOL Webinar on Sickle Cell Disease: The Changing Landscape and Need for New Treatments

Dublin, Ireland, 29 Mar 2023: Afimmune, a privately held, clinical stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it will host a […]
January 4, 2023

Afimmune Confirm Alignment with FDA on Planned Pivotal Trial of Epeleuton in Sickle Cell Disease Patients

Afimmune looking to initiate Pivotal study in 2023 Dublin, Ireland, 4 January 2023: Afimmune, a privately held, clinical stage biopharmaceutical company developing novel therapeutics for the […]
September 19, 2022

Epeleuton receives orphan-drug designation for Sickle Cell Disease from the EMA

Dublin, Ireland, 19 September 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted orphan drug designation […]
July 19, 2022

Epeleuton receives orphan-drug designation for Sickle Cell Disease from the FDA

Dublin, Ireland, 19 July 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) in the United States […]
June 10, 2022

Data Showing Epeleuton As A Potential Treatment For Sickle Cell Disease Will Be Presented At The EHA 2022 Congress

Dublin, Ireland, 10 June 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]
August 26, 2021

Afimmune’s Epeleuton shows large decreases in viral load and pathological changes in COVID-19 study

Epeleuton decreases viral titres and SARS-CoV-2 RNA and histopathological damage in the upper and lower respiratory tract Dublin, Ireland, 26th August 2021 – Afimmune, a clinical stage drug discovery […]
December 18, 2018

Afimmune receives method of use patent allowance for Oral AF102 in the US

Dublin, Ireland, 18th December 2018 – Afimmune, a privately held clinical stage drug discovery and development company, today announced receipt of allowance for a patent application in […]
October 18, 2017

Afimmune receives a patent allowance for Oral AF102 in the US

Dublin, Ireland, 18th October 2017 – Afimmune (AF), a privately held drug discovery and development company, today announced receipt of allowance for a patent application in […]
December 18, 2015

Afimmune announces successful completion of a Phase I safety study with bioactive lipid DS102

Dublin, Ireland, December 18th, 2015 – Afimmune, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation […]